Immunosyn Corporation (IMYN.OB) Relies on Additional Financing
13 May 2010

Immunosyn Corporation (IMYN.OB) relies on its affiliates to provide financial support for the company’s future projects.

IMNY’s funds have not been sufficient to cover its expenses that resulted in an over $ 2 million net loss last year. To continue its current limited operations, the company needs additional financing.

The chart shows significant changes in volume during the last few months. The average traded volume for this period has been much lower, while in May it reached top values. For example, in March, 2010 the traded volume went down to 11 thousand, and in May, 2010 it reached over 175 thousand shares. Yesterday the price change went up +3.23% and the market cap pointed 342.47m. The IMYN’s stocks closed at $ 1.28, which is $ 0.04 higher than the days before.

Still these values have been quite variable, which make the sudden uptrend questionable. By 16 April, 2010 Immunosyn Corporation has had no revenue and limited operations, and last year the company had a negative working capital. Currently, an affiliated company provides general support services to IMYN, with no charge.

As Immunosyn Corporation is a development stage company, it has received advances from Argyll Equities, LLC and Argyll Biotech who own approximately 59% of its stocks. The primary aim of INMY is to expand its operations and establish a market position for approval and distribution of SF-1019. Yet the company requires between $14 million and $24 million additional capital to meet its anticipated expenditures. Failure to obtain future financing will require IMYN to delay or close its business.


No comments
Leave a comment

*
To prove you're a person (not a spam script), type the security word shown in the picture. Click on the picture to hear an audio file of the word.
Click to hear an audio file of the anti-spam word